FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2022/08/044838 [Registered on: 23/08/2022] Trial Registered Prospectively
Last Modified On: 23/08/2022
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Other (Specify) [Cosmeceuitcal]  
Study Design  Single Arm Study 
Public Title of Study   Evaluation of safety and efficacy of skin care formulation 
Scientific Title of Study   PRIMARY OBJECTIVE To evaluate the in-vivo efficacy and safety of a skin care formulation in terms of in terms of skin brightening on healthy female subjects. SECONDARY OBJECTIVE To evaluate the in-vivo efficacy of a skin care formulation in terms of improvement in skin hydration and improvement in skin smoothness on healthy female subjects. 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
XXX-NF02-DT-FR22; Version: Final 01; Dated: 21/07/2022 .   Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Raji Patil 
Designation  Investigator  
Affiliation  MASCOT-SPINCONTROL India Pvt. Ltd.  
Address  Kohinoor Estate, 3rd Floor, Sun Mill Compound, Lower Parel West, Mumbai. Mumbai (Suburban) MAHARASHTRA 400013 India

Mumbai
MAHARASHTRA
400013
India 
Phone  02243349191   
Fax    
Email  raji@mascotspincontrol.in  
 
Details of Contact Person
Scientific Query
 
Name  Dr Raji Patil 
Designation  Investigator  
Affiliation  MASCOT-SPINCONTROL India Pvt. Ltd.  
Address  Kohinoor Estate, 3rd Floor, Sun Mill Compound, Lower Parel West, Mumbai. Mumbai (Suburban) MAHARASHTRA 400013 India


MAHARASHTRA
400013
India 
Phone  02243349191   
Fax    
Email  raji@mascotspincontrol.in  
 
Details of Contact Person
Public Query
 
Name  Dr Mohit Lalvani  
Designation  Study Director  
Affiliation  MASCOT-SPINCONTROL India Pvt. Ltd.  
Address  Kohinoor Estate, 3rd Floor, Sun Mill Compound, Lower Parel West, Mumbai. Mumbai (Suburban) MAHARASHTRA 400013 India

Mumbai
MAHARASHTRA
400013
India 
Phone  02243349191   
Fax    
Email  mohit.CTRI@gmail.com  
 
Source of Monetary or Material Support  
MASCOT-SPINCONTROL India Pvt. Ltd. Kohinoor Estate, 3rd Floor, Sun Mill Compound, Lower Parel West, Mumbai. Mumbai (Suburban) MAHARASHTRA 400013 India  
 
Primary Sponsor  
Name  DPKA Universal Consumer Ventures Private Limited 
Address  3002, 30th Floor, Beau Monde, Tower B, Prabhadevi Road, Prabhadevi, Mumbai – 400025.  
Type of Sponsor  Other [FMCG] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  Not applicable 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Raji Patil   Mascot Spincontrol India Pvt. Ltd.   Kohinoor Estate, 3rd Floor, Sun Mill Compound, Lower Parel West, Mumbai. Mumbai (Suburban) MAHARASHTRA 400013 India
Mumbai
MAHARASHTRA 
02243349191

raji@mascotspincontrol.in 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Ethos- An Institutional Ethics committee (Mumbai)   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Healthy Human Volunteers  Having wheatish to dark complexion, having dry skin 10 Females with sensitive skin  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  NIL  Not applicable 
Intervention  Standard Moisturizer  In study duration of 28 days approx. 0.5 to 1 gm of sponsor provided standard moisturizer to be used. 
Intervention  Standard Face Wash  In study duration of 28 days face has to be cleaned with sponsor provided standard face wash. 
Intervention  Sunscreen Serum  Approximately 0.5-1gm of the product to be applied on whole face The test product to be applied thrice in a day in the morning, afternoon & evening (every 4hours while in the sun) for the period of 28 days.  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  50.00 Year(s)
Gender  Female 
Details  1 Indian Female subjects.
2 Healthy subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup)
3 Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar, acne….) Specific criteria
4 Having wheatish to dark complexion.
5 Having dry skin.
6 Subjects who are passing in skin sensitivity test (only for 13 females)
 
 
ExclusionCriteria 
Details 
1 Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
2 Having refused to give her assent by not signing the consent form
3 Taking part in another study liable to interfere with this study
4 Being insulin-dependent diabetic or non insulin-dependent diabetic with a recent therapy (less than 6 months)
5 Having a progressive asthma (either under treatment or last fit in the last 2 years)
6 Being epileptic.
7 Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months)
8 Having cutaneous hypersensitivity
9 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
10 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol)
11 Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months.
12 Having changed her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit
13 Having applied a cosmetic product (included make-up) or skin care product on the studied areas the day of the study (only face cleaned with water is accepted)
14 Refusing to follow the restrictions below during the study: -Do not take part in any family planning activities leading to pregnancy and breastfeeding -Do not take part in another study liable to interfere with this study. -Do not take medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol). -Do not change her cosmetic habits apart from the particular conditions mentioned in the protocol, on the studied anatomic unit. -During the study: Do not use other cosmetic products or skin care products other than the tested products to the studied areas. (only standard facewash is accepted). The day of the measurements: No test product must be used (only face cleaned with water is accepted) Specific criteria
15 Having started, changed or interrupted one hormonal treatment (hormonal contraception, Hormone Replacement Therapy) during the past 3 months.
16 Having started, changed or stopped his/her tobacco consumption (for smokers consuming more than 10 cigarettes per day) in the previous 6 months
17 Having taken a medicinal treatment which could lead to hyper pigmentation (phenytoïn, amiodarone, metals, minocycline…) in the previous 6 months
18 Taking oral supplements with major or minor effect on whitening of skin (e.g. vitamin C, beta carotene…)
19 Having had beauty treatment (e.g. skin cleansing, exfoliation, scrub, mask …) or having applied self-tanning products in the week preceding the start of the study
20 Having applied products with anti-wrinkle action (Retinoic acid, retinol, retinaldehyde, isotretinoin, A.H.A...) in the 2 weeks preceding the start of the study
21 Having applied products with a depigmenting action (hydroquinone or derivates…) in the 4 weeks preceding the start of the study.
22 Having undergone physical and/or chemical treatments of the spots (liquid nitrogen, dry ice, pulsed flash lamp, dermabrasion, chemical peel …) in the previous 6 months
23 Having a suntanned skin on the studied areas which could interfere with the evaluations of the study
24 Refusing to follow the restrictions below during the study: - Do not start, change or stop a hormonal treatment (hormonal contraception, Hormone Replacement Therapy) - Do not start a medicinal treatment which could lead to hyper pigmentation - Do not use products or techniques or surgery with a depigmenting - Do not take oral supplements with major or minor effect on whitening of skin (e.g. vitamin C, beta-carotene…) - Do not have beauty treatment (e.g. skin cleansing, exfoliation, scrub, mask …) or apply self tanning products action. - Do not swim in artificial water bodies (pools, hot tubs etc.…) - Do not expose herself to the sun by respecting a strict photo-protection
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
skin brightening, skin safety  Baseline, 30 min after product application, 7 days, 14 days and 28 days 
 
Secondary Outcome  
Outcome  TimePoints 
improvement in skin hydration
and improvement in skin smoothness 
Baseline, 30 min after product application, 7 days, 14 days and 28 days 
 
Target Sample Size   Total Sample Size="56"
Sample Size from India="56" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   28/08/2022 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="3"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   Nil 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

PRIMARY OBJECTIVE To evaluate the in-vivo efficacy and safety of a skin care formulation in terms of in terms of skin brightening on healthy female subjects.

SECONDARY OBJECTIVE To evaluate the in-vivo efficacy of a skin care formulation in terms of improvement in skin hydration and improvement in skin smoothness on healthy female subjects.

Test Product: SUNSCREEN LOTION: Product A

The evaluation is performed using: Subject’s Self Evaluation, Dermatological Evaluation: Safety, Dermatological Evaluation: Efficacy, Chromametry, Corneometry.

Total duration of the study: 28 days following the first application of product.

Kinetics: T0, T+30 minutes after product application, T+7 days, T+14 days and T+28 days 

Number of volunteers: 56 (43 normal skin volunteers +13 sensitive skin)

 
Close